Does this PCSA Form 4 show any insider share sales by David Young?

No, the filing only reports a buy-side transaction. The Form 4 lists one open-market purchase of 1,545 common shares at $2.97 per share, with no reported sales or derivative exercises on April 15, 2026.

Processa Pharmaceuticals (NASDAQ: PCSA) R&D chief buys 1,545 shares in open market

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of 1,545 shares of common stock at $2.97 per share on April 15, 2026. After this trade, he holds 12,107 shares directly, plus indirect holdings of 1,242 shares via the Young-Plaisance Revocable Trust, 432 shares via family entities, and 742 shares via CorLyst, LLC.

Insider Trade Summary

Net Buyer: 1,545 shares ($4,589)

Net Buy 4 txns

Insider Young David

Role Pres. Research & Development

Bought 1,545 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,545	$2.97	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 12,107 shares (Direct); Common Stock — 1,242 shares (Indirect, By Young-Plaisance Revocable Trust)

Footnotes (1)

Key Figures

Open-market purchase: 1,545 shares Purchase price: $2.97 per share Direct holdings after trade: 12,107 shares +3 more

6 metrics

Open-market purchase 1,545 shares Common Stock bought at $2.97 on April 15, 2026

Purchase price $2.97 per share Open-market buy of Processa Pharmaceuticals common stock

Direct holdings after trade 12,107 shares Common Stock directly owned following April 15, 2026 purchase

Trust holdings 1,242 shares Indirect ownership by Young-Plaisance Revocable Trust

Family entities holdings 432 shares Indirect ownership by family entities

CorLyst, LLC holdings 742 shares Indirect ownership by CorLyst, LLC

Key Terms

open-market purchase, indirect ownership, revocable trust, Form 4, +1 more

5 terms

open-market purchase financial

"reported an open-market purchase of 1,545 shares of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"indirect holdings of 1,242 shares via the Young-Plaisance Revocable Trust"

revocable trust financial

"1,242 shares via the Young-Plaisance Revocable Trust"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Form 4 regulatory

"The Form 4 shows an open-market purchase of 1,545 shares"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

common stock financial

"purchase of 1,545 shares of common stock at $2.97 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

04/17/2026 - 04:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young David

(Last)

(First)

(Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH

FLORIDA

32960

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Pres. Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/15/2026		P		1,545	A	$2.97	12,107	D
Common Stock								1,242	I	By Young-Plaisance Revocable Trust
Common Stock								432	I	By Family Entities
Common Stock								742	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ David Young by John J. Wolfel, as Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PCSA executive David Young report on this Form 4?

David Young reported an open-market purchase of 1,545 shares of Processa Pharmaceuticals common stock. The shares were bought at $2.97 per share on April 15, 2026, increasing his directly held ownership stake in the company.

At what price did David Young buy Processa Pharmaceuticals (PCSA) shares?

David Young bought Processa Pharmaceuticals common stock at $2.97 per share. The Form 4 shows an open-market purchase of 1,545 shares on April 15, 2026, reflecting the price he paid in that transaction.

How many Processa Pharmaceuticals (PCSA) shares does David Young own directly after this trade?

After the reported transaction, David Young directly owns 12,107 shares of Processa Pharmaceuticals common stock. This figure comes from the Form 4 entry showing total shares following the April 15, 2026 open-market purchase.

What indirect Processa Pharmaceuticals (PCSA) holdings are associated with David Young?

Indirect holdings associated with David Young include 1,242 shares held by the Young-Plaisance Revocable Trust, 432 shares held by family entities, and 742 shares held by CorLyst, LLC. These positions are reported as indirect ownership on the Form 4.

What is David Young’s role at Processa Pharmaceuticals (PCSA)?

David Young is both a director and the Pres. Research & Development at Processa Pharmaceuticals. His dual role as officer and director is disclosed in the Form 4 reporting his recent open-market share purchase.